CN103370320A - 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 - Google Patents
芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 Download PDFInfo
- Publication number
- CN103370320A CN103370320A CN2011800646282A CN201180064628A CN103370320A CN 103370320 A CN103370320 A CN 103370320A CN 2011800646282 A CN2011800646282 A CN 2011800646282A CN 201180064628 A CN201180064628 A CN 201180064628A CN 103370320 A CN103370320 A CN 103370320A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(NC1=Nc(c(O*)c(cc2)O*)c2C2=NCCN12)=O Chemical compound *C(NC1=Nc(c(O*)c(cc2)O*)c2C2=NCCN12)=O 0.000 description 1
- ZXFSUWTUNNYWKZ-HZSPNIEDSA-N C[C@H]1O[C@@H](C)CN(C[C@H](COc(ccc2c3N=C(N)N4C2=NCC4)c3OC)O)C1 Chemical compound C[C@H]1O[C@@H](C)CN(C[C@H](COc(ccc2c3N=C(N)N4C2=NCC4)c3OC)O)C1 ZXFSUWTUNNYWKZ-HZSPNIEDSA-N 0.000 description 1
- VZBNUEHCOOXOHR-SSDOTTSWSA-N OC[C@@H](CN1CCOCC1)O Chemical compound OC[C@@H](CN1CCOCC1)O VZBNUEHCOOXOHR-SSDOTTSWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41250210P | 2010-11-11 | 2010-11-11 | |
US61/412,502 | 2010-11-11 | ||
PCT/EP2011/069632 WO2012062743A1 (en) | 2010-11-11 | 2011-11-08 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103370320A true CN103370320A (zh) | 2013-10-23 |
CN103370320B CN103370320B (zh) | 2016-04-27 |
Family
ID=44999754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180064628.2A Expired - Fee Related CN103370320B (zh) | 2010-11-11 | 2011-11-08 | 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9675616B2 (und) |
EP (1) | EP2638043B1 (und) |
JP (1) | JP5940078B2 (und) |
CN (1) | CN103370320B (und) |
CA (1) | CA2817287A1 (und) |
ES (1) | ES2639402T3 (und) |
HK (1) | HK1190712A1 (und) |
WO (1) | WO2012062743A1 (und) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
CA2817312A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Intellectual Property Gmbh | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
KR102206432B1 (ko) * | 2012-11-30 | 2021-01-22 | 노파르티스 아게 | 신규 제약 조성물 |
CA2908640A1 (en) * | 2013-04-05 | 2014-10-09 | Sanofi | Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor |
CN105934256B (zh) | 2013-12-03 | 2019-12-27 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
EP3077003A1 (en) | 2013-12-03 | 2016-10-12 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
WO2021260443A1 (en) * | 2020-06-24 | 2021-12-30 | Bayer Aktiengesellschaft | Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
WO2010034414A1 (en) * | 2008-09-24 | 2010-04-01 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
MXPA06003705A (es) * | 2003-10-03 | 2006-06-20 | 3M Innovative Properties Co | Imidazoquinolinas sustituidas con alcoxi. |
EP1719771A1 (en) * | 2004-02-19 | 2006-11-08 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
CA2817312A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Intellectual Property Gmbh | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
-
2011
- 2011-11-08 CA CA2817287A patent/CA2817287A1/en not_active Abandoned
- 2011-11-08 EP EP11784976.0A patent/EP2638043B1/en not_active Not-in-force
- 2011-11-08 US US13/884,125 patent/US9675616B2/en not_active Expired - Fee Related
- 2011-11-08 WO PCT/EP2011/069632 patent/WO2012062743A1/en active Application Filing
- 2011-11-08 CN CN201180064628.2A patent/CN103370320B/zh not_active Expired - Fee Related
- 2011-11-08 ES ES11784976.0T patent/ES2639402T3/es active Active
- 2011-11-08 JP JP2013538161A patent/JP5940078B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-22 HK HK14103827.7A patent/HK1190712A1/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
WO2010034414A1 (en) * | 2008-09-24 | 2010-04-01 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
Also Published As
Publication number | Publication date |
---|---|
EP2638043A1 (en) | 2013-09-18 |
CN103370320B (zh) | 2016-04-27 |
EP2638043B1 (en) | 2017-06-07 |
JP2013542236A (ja) | 2013-11-21 |
US20140113896A1 (en) | 2014-04-24 |
JP5940078B2 (ja) | 2016-06-29 |
WO2012062743A1 (en) | 2012-05-18 |
US9675616B2 (en) | 2017-06-13 |
CA2817287A1 (en) | 2012-05-18 |
HK1190712A1 (zh) | 2014-07-11 |
ES2639402T3 (es) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102906094B (zh) | 用于治疗过度增殖性病症和与血管发生相关的疾病的氨基醇取代的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物 | |
CN103370320B (zh) | 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 | |
CN105263497B (zh) | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途 | |
CN101631464B (zh) | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 | |
CN103608018B (zh) | 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的用途 | |
JP5620275B2 (ja) | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類 | |
CN103339133B (zh) | 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1190712 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1190712 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160427 Termination date: 20181108 |